WebDec 1, 2024 · Introduction: BT1718 is a targeted Bicycle peptide-conjugate designed to deliver the anti-tubulin agent, DM1 to tumors expressing membrane type 1-matrix metalloprotease (MT1-MMP; MMP14; MT1). In vivo preclinical studies demonstrated that anti-tumor activity of BT1718 is dependent on the level of tumor MT1-MMP expression. WebFeb 13, 2024 · The trial is co-managed by Cancer Research UK and Bicycle Therapeutics. Under the terms of the agreement, Bicycle retains the right to further advance the BT1718 program, at which point an undisclosed payment split between cash and equity, success based milestones and royalty payments would be made to Cancer Research UK. …
Bicycle Therapeutics to Present at the 2024 AACR Annual Meeting
WebSep 2, 2024 · BT1718 is a BTC targeting MT1-MMP and is comprised of a mono-hindered disulfide cleavable linker and a cytotoxic DM1 payload. The Phase IIa expansion will … WebFeb 1, 2024 · BT1718 is a novel bicyclic peptide anticancer drug targeting membrane type I matrix metalloproteinase to release its toxic payload DM1. BT5528 has shown … honda clubman gb 500
Stock Market FinancialContent Business Page
WebOct 1, 2024 · BT1718 contains a constrained bicyclic peptide with high affinity and selectivity for cell surface target MT1-MMP (MMP14) linked to a toxin (DM1) via a cleavable … WebBackground: BT1718 is a novel bicyclic peptide anticancer drug targeting membrane type I matrix metalloproteinase to release its toxic payload DM1. A LC-MS/MS method was … WebBT1718 in Patients With Advanced Solid Tumours. Latest version (submitted August 16, 2024) on ClinicalTrials.gov A study version is represented by a row in the table. Select … history 1739